IDEAYA: darovasertib combo meets primary endpoint in mUM; Q2 net loss $112.5M; cash $1.24B

IDEAYA Biosciences, Inc.

Registrational OptimUM-02 trial met primary endpoint: median PFS 6.9 vs 3.1 months (HR 0.42, p<0.0001); NDA filing underway under RTOR.
Q2 2026 net loss $112.5M vs $98.5M in Q1; R&D expenses $108.7M; G&A $22.5M.
Cash, cash equivalents and marketable securities $1.24B as of June 30, 2026; cash runway into 2030 unchanged.
Clinical collaboration with Roche to evaluate IDE892 + RG6505 in MTAP-deleted, RAS-mutant PDAC; Phase 1 combo trial to start H2 2026.
Updated data from IDE849 (DLL3 ADC) and OptimUM-01/09 at ESMO; Phase 3 registrational trial for IDE849 targeted by end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.